102 related articles for article (PubMed ID: 12952219)
1. Predicting treatment responses and disease progression in myeloma using serum vascular endothelial growth factor and hepatocyte growth factor levels.
Iwasaki T; Sano H
Leuk Lymphoma; 2003 Aug; 44(8):1275-9. PubMed ID: 12952219
[TBL] [Abstract][Full Text] [Related]
2. Predicting treatment responses and disease progression in myeloma using serum vascular endothelial growth factor and hepatocyte growth factor levels.
Iwasaki T; Sano H
Leuk Lymphoma; 2003 Aug; 44(8):1347-51. PubMed ID: 12952228
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma.
Iwasaki T; Hamano T; Ogata A; Hashimoto N; Kitano M; Kakishita E
Br J Haematol; 2002 Mar; 116(4):796-802. PubMed ID: 11886383
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas.
Ren Y; Cao B; Law S; Xie Y; Lee PY; Cheung L; Chen Y; Huang X; Chan HM; Zhao P; Luk J; Vande Woude G; Wong J
Clin Cancer Res; 2005 Sep; 11(17):6190-7. PubMed ID: 16144920
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma.
Sezer O; Jakob C; Eucker J; Niemöller K; Gatz F; Wernecke K; Possinger K
Eur J Haematol; 2001 Feb; 66(2):83-8. PubMed ID: 11168514
[TBL] [Abstract][Full Text] [Related]
6. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
Alexandrakis MG; Sfiridaki A; Miyakis S; Pappa C; Kandidaki E; Alegakis A; Margioris AN
Clin Chim Acta; 2007 Apr; 379(1-2):31-5. PubMed ID: 17234170
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
Dong G; Chen Z; Li ZY; Yeh NT; Bancroft CC; Van Waes C
Cancer Res; 2001 Aug; 61(15):5911-8. PubMed ID: 11479233
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow microvascular density and angiogenic growth factors in multiple myeloma.
Alexandrakis MG; Passam FJ; Ganotakis E; Dafnis E; Dambaki C; Konsolas J; Kyriakou DS; Stathopoulos E
Clin Chem Lab Med; 2004; 42(10):1122-6. PubMed ID: 15552270
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of hepatocyte growth factor, platelet-derived growth factor-AB, and transforming growth factor-alpha in bone marrow and peripheral blood of patients with multiple myeloma.
Kara IO; Sahin B; Gunesacar R; Unsal C
Adv Ther; 2006; 23(4):635-45. PubMed ID: 17050506
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia.
Zhelyazkova AG; Tonchev AB; Kolova P; Ivanova L; Gercheva L
Scand J Clin Lab Invest; 2008; 68(6):492-500. PubMed ID: 18609087
[TBL] [Abstract][Full Text] [Related]
11. Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.
Saltarella I; Morabito F; Giuliani N; Terragna C; Omedè P; Palumbo A; Bringhen S; De Paoli L; Martino E; Larocca A; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Grasso M; Leonardi G; Rizzo M; Falcone AP; Gottardi D; Montefusco V; Musto P; Petrucci MT; Dammacco F; Boccadoro M; Vacca A; Ria R
J Hematol Oncol; 2019 Jan; 12(1):4. PubMed ID: 30626425
[TBL] [Abstract][Full Text] [Related]
12. The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma.
Scudla V; Pika T; Budikova M; Petrova J; Minarik J; Bacovsky J; Langova K; Zivna J;
Neoplasma; 2010; 57(2):102-10. PubMed ID: 20099972
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor.
Tanimoto S; Fukumori T; El-Moula G; Shiirevnyamba A; Kinouchi S; Koizumi T; Nakanishi R; Yamamoto Y; Taue R; Yamaguchi K; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Takahashi M; Kanayama HO
J Med Invest; 2008 Feb; 55(1-2):106-11. PubMed ID: 18319552
[TBL] [Abstract][Full Text] [Related]
14. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response.
Pour L; Svachova H; Adam Z; Almasi M; Buresova L; Buchler T; Kovarova L; Nemec P; Penka M; Vorlicek J; Hajek R
Ann Hematol; 2010 Apr; 89(4):385-9. PubMed ID: 19784651
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.
Dankbar B; Padró T; Leo R; Feldmann B; Kropff M; Mesters RM; Serve H; Berdel WE; Kienast J
Blood; 2000 Apr; 95(8):2630-6. PubMed ID: 10753844
[TBL] [Abstract][Full Text] [Related]
16. The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma.
Tsirakis G; Pappa CA; Kaparou M; Boula A; Katsomitrou V; Xekalou A; Kyriakaki S; Alexandrakis MG
Tumour Biol; 2013 Apr; 34(2):859-64. PubMed ID: 23242610
[TBL] [Abstract][Full Text] [Related]
17. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
18. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
[TBL] [Abstract][Full Text] [Related]
19. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma.
Pour L; Svachova H; Adam Z; Mikulkova Z; Buresova L; Kovarova L; Buchler T; Penka M; Vorlicek J; Hajek R
Neoplasma; 2010; 57(1):29-34. PubMed ID: 19895169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
